红花籽油可改善代谢综合征患者的腹型肥胖、血压和胰岛素抵抗：一项随机、双盲、安慰剂对照的临床试验。
Safflower (Carthamus tinctorius L.) oil could improve abdominal obesity, blood pressure, and insulin resistance in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled clinical trial.
机构信息
Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Internal Medicine, Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Traditional Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Internal Medicine, Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
出版信息
J Ethnopharmacol. 2022 Jan 10;282:114590. doi: 10.1016/j.jep.2021.114590. Epub 2021 Sep 4.
ETHNOPHARMACOLOGICAL RELEVANCE
Carthamus tinctorius L. (Safflower) has been widely recommended to treat metabolic disorders in traditional herbal medicine in Persia, China, Korea, Japan, and other East-Asian countries. The anti-hypercholesterolemic and antioxidant effects of this plant have been well documented, but its protective effects against Metabolic Syndrome (MetS) have not been fully illustrated.
AIM OF THE STUDY
The present study aimed to evaluate the effects of safflower oil on MetS risk factors.
MATERIALS AND METHODS
In this randomized, double-blind, placebo-controlled clinical trial, 67 patients with MetS were administered either divided 8 g safflower oil or placebo daily for 12 weeks. All patients were advised to follow their previous diets and physical activities.
RESULTS
Safflower oil resulted in a significant reduction in waist circumference (-2.42 ± 3.24 vs. 0.97 ± 2.53, p<0.001), systolic blood pressure (-8.80 ± 9.77 vs. -2.26 ± 8.56, p = 0.021), diastolic blood pressure (-3.53 ± 7.52 vs. -0.70 ± 6.21, p = 0.041), fasting blood sugar (-5.03 ± 10.62 vs. 2.94 ± 7.57, p = 0.003), and insulin resistance (-0.59 ± 1.43 vs. 0.50 ± 1, p = 0.012), but an increase in adiponectin level (0.38 ± 0.99 vs. -0.09 ± 0.81, p = 0.042) in the treatment group in comparison to the placebo group. The results revealed a direct relationship between leptin level and Body Mass Index (BMI) in both groups (p<0.001). In addition, increase in BMI resulted in a non-significant decrease in adiponectin level in both groups. Moreover, no significant difference was observed between the two groups regarding lipid profiles, leptin serum level, serum creatinine concentration, and other outcomes.
CONCLUSION
Safflower oil without lifestyle modification improved abdominal obesity, blood pressure, and insulin resistance in patients with MetS.
民族药理学相关性
红花（红花）在波斯、中国、韩国、日本和其他东亚国家的传统草药医学中被广泛推荐用于治疗代谢紊乱。该植物的降胆固醇和抗氧化作用已有充分的记载，但它对代谢综合征（MetS）的保护作用尚未完全阐明。
研究目的
本研究旨在评估红花油对 MetS 危险因素的影响。
材料和方法
在这项随机、双盲、安慰剂对照的临床试验中，67 名 MetS 患者每天服用 8g 红花油或安慰剂，持续 12 周。所有患者均被建议遵循之前的饮食和体育活动。
结果
红花油可显著降低腰围（-2.42±3.24 对 0.97±2.53，p<0.001）、收缩压（-8.80±9.77 对-2.26±8.56，p=0.021）、舒张压（-3.53±7.52 对-0.70±6.21，p=0.041）、空腹血糖（-5.03±10.62 对 2.94±7.57，p=0.003）和胰岛素抵抗（-0.59±1.43 对 0.50±1，p=0.012），但治疗组的脂联素水平升高（0.38±0.99 对-0.09±0.81，p=0.042）。与安慰剂组相比，结果显示两组中瘦素水平与体重指数（BMI）之间存在直接关系（p<0.001）。此外，两组中 BMI 的增加导致脂联素水平的非显著性下降。此外，两组之间在血脂谱、瘦素血清水平、血清肌酐浓度和其他结果方面没有显著差异。
结论
不改变生活方式的红花油可改善 MetS 患者的腹部肥胖、血压和胰岛素抵抗。
Zotero 插件